Empowering appropriate antimicrobial use with rapid diagnostics.

Rapid Testing

Early and rapid diagnosis of CAP would allow more directed therapy and confidence in appropriate treatment for a majority of patients.1 Using an appropriate pathogen-focused antibiotic or narrowing empirical therapy may decrease cost, drug adverse events, and the threat of antibiotic resistance.2 

Alere BinaxNOW S. pneumoniae

A rapid and simple urine antigen test (UAT), Alere BinaxNOW® S. pneumoniae based on immunochromatographic technique, is widely available to detect the C-polysaccharide antigen of S. pneumoniae in just 15 minutes. The high specificity, positive predictive value, and positive likelihood ratio makes Alere BinaxNOW® S. pneumoniae a useful tool in the treatment of adult patients with CAP. The Alere BinaxNOW® S. pneumoniae Urinary Antigen Card can be read visually or with the Alere™ Reader.*

In one study, the Alere BinaxNOW® UAT was the only diagnostic test positive for

S. pneumoniae for 32 patients. Had this test not been available, these patients would have received diagnoses of pneumonia due to atypical pathogens or unknown etiology, and according to current guidelines, would have received broad-spectrum antibiotic therapy. However, these patients fared just as well receiving a penicillin.3

Alere BinaxNOW® S. pneumoniae is advocated by numerous worldwide CAP guidelines including IDSA/ATS, BTS, SPILF and SEPAR. The IDSA/ATS CAP guidelines conclude that only 50% of Alere BinaxNOW® S. pneumoniae UAT positive patients can be diagnosed by conventional methods.4

*Only available in select markets.